4. OptiScan bedside monitoring system
OptiScan Biomedical’s bedside glucose monitoring system may have similar concepts to other CGM devices, but its impact in hospitals could be where the device is set apart from the rest.
The OptiScanner 5000 is an automated bedside blood glucose monitor designed for use in the intensive care unit. The system is designed to measure glucose values from a micro-sample of blood without the need for calibration, according to OptiScan.
OptiScan’s device is plasma-based, designed to directly measure glucose levels in blood plasma. Its mid-infrared spectroscopy does away with the calibration that is common in other similar technologies, according to the company, and it automatically measures and trends glucose every 15 minutes, delivering an early warning system to support proactive intervention.
In March 2019, the company closed a $20 million Series E round to support the commercialization of the OptiScanner 5000 in the U.S. The bedside monitor also has CE Mark approval in Europe.